Latest news

Search
Categories
News archive

Interim Report Q1 2025

16 April, 2025

FINANCIAL SUMMARY Net sales for the first quarter amounted to SEK 10,751 thousand (5,037) The operating loss amounted to SEK 9,241 thousand (15,331) Loss after tax amounted to SEK 10,171 thousand (16,734) Earnings per share before and after dilution were SEK -0.12 (-0.46) Cash and cash equivalents per 31 March 2024 amounted to SEK 28,348 thousand (23,600). Shortly after the end of the quarter, the company’s cash and cash equivalents increased by approximately SEK 7

Read more »

CEO Comment Annual Report 2024

28 March, 2025

After many years of working with various technologies and products, Nanologica has developed into a pure chromatography company with products for purification of pharmaceuticals during production, on a global market. Today we provide pharmaceutical manufacturers with products that needed to manufacture  fast-growing GLP-1 analogues and insulin. With these products and our expertise in method and application development, we can streamline our customers’ workflows and reduce their costs. This makes us relevant in a market characterized

Read more »

CEO Comment Q4 2024

14 February, 2025

SALES RECORD FOR CHROMTOGRAPHY PRODUCTS In 2024, we reached our highest sales of chromatography products ever with net sales of SEK 14.5 million, of which SEK 6.7 million in the fourth quarter. Sales of our silica media NLAB Saga® were able to start during the summer after we finalized and approved significantly larger volumes of silica than before from our large-scale production facility. Production of silica has continued to stabilize during the year, which has

Read more »